Infant Formula Production Stalls On Reckitt Benckiser's Latest Stumble
This article was originally published in The Rose Sheet
Executive Summary
A "technical problem" interrupted infant formula production at firm's Netherlands plant during third quarter, causing a 8% dive in its revenues from Enfamil and other brand formulas. The problem has been corrected but revenues will be slowed during the current quarter and likely into early 2019. But analysts say the imapct could be deeper impact because it's the fourth problems since 2011 RB should have avoided.
You may also be interested in...
Reckitt's New CEO Wants Immediate Changes As OTC Sales Slump In Q3
RB's new CEO Laxman Narasimhan is unforgiving about how the company has been run over the past few years and believes things need to change after another disappointing quarter.
RB's OTC Sales Slump 9% In Q1 As Cold Season Fails To Materialize
Reckitt Benckiser was hit badly by the weak cold and flu season in the US and Europe at the start of 2019, causing its OTC sales to drop by 9%. Despite supplement sales also struggling, the firm insists it will still hit its revenue targets for the full year, with growth expected in the second half.
Reckitt ‘Not Happy’ With Consumer Health Growth In 2018, Following European And Infant Nutrition Woes
RB's Health business failed to keep pace with market growth in 2018, with the firm admitting its mindset in Europe "needs to change." The UK-based consumer-goods giant spent the 12 months working on its RB 2.0 restructuring program, which will give it the option to separate into two independent companies focusing on Health and Hygiene by 2020.